Loading...
LXEO logo

Lexeo Therapeutics, Inc.NasdaqGM:LXEO Stock Report

Market Cap US$378.5m
Share Price
n/a
1Y7.8%
7D2.8%
1D-4.6%
Portfolio Value
​
View

Lexeo Therapeutics, Inc.

NasdaqGM:LXEO Stock Report

Market Cap: US$378.5m

Lexeo Therapeutics (LXEO) Stock Overview

A clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. More details

LXEO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 81.1% below our estimate of its fair value

Revenue is forecast to grow 65.61% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years


LXEO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW491,113 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
491,113 investors already sharing narratives
View all narratives

Lexeo Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lexeo Therapeutics
Historical stock prices
Current Share PriceUS$4.82
52 Week HighUS$10.99
52 Week LowUS$3.60
Beta1.43
1 Month Change10.30%
3 Month Change-24.45%
1 Year Change7.83%
3 Year Changen/a
5 Year Changen/a
Change since IPO-52.04%

Recent News & Updates

Seeking Alpha • Jun 22

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline

Summary Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027. Also, LX2006’s early Phase 1/2 data were promising. The main caveat is that their dataset is small, and the subsequent pivotal study is open-label. I feel LXEO’s progress on LX2006 is quite promising. And they should have enough financing to reach LX2006’s 2027 readout, which is why I’m bullish. Read the full article on Seeking Alpha
Analysis Article • Jun 03

Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Seeking Alpha • Jun 22

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline

Summary Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027. Also, LX2006’s early Phase 1/2 data were promising. The main caveat is that their dataset is small, and the subsequent pivotal study is open-label. I feel LXEO’s progress on LX2006 is quite promising. And they should have enough financing to reach LX2006’s 2027 readout, which is why I’m bullish. Read the full article on Seeking Alpha
Analysis Article • Jun 03

Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 25

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 20

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Oct 11

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 16

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Summary Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in several cardiac biomarkers. The global Friedreich's ataxia market is expected to reach $3.39 billion by 2034. Additional interim results, along with cardiac biopsy assessment in FA patients with LX2006, expected at an upcoming medical conference presentation in Fall of 2024. Interim results from two other programs expected in the 2nd half of 2024 are LX1001 for APOE4-associated Alzheimer's Disease and LX2020 for PKP2 arrhythmogenic cardiomyopathy. Read the full article on Seeking Alpha
Analysis Article • Jun 18

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Apr 09

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Summary Lexeo Therapeutics, Inc. has results from its phase 1/2 SUNRISE-FA study, using LX-2006 for the treatment of patients with FA cardiomyopathy, expected in mid-2024. Results from all cohorts of phase 1/2 LEAD study, using LX-1001 for the treatment of patients with homozygous APOE4 AD, expected 2nd half of 2024. The global Alzheimer's Disease market is expected to reach $9.73 billion by 2030; It is said that between 15% to 25% of AD patients have this allele. Initiation of phase 1/2 HEROIC-PKP2 study, using LX-2020 for the treatment of patients with arrhythmogenic cardiomyopathy expected 1st half of 2024; Interim data to be released from cohort 1 in second half of 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's

Summary Lexeo is a small company developing gene therapies for Alzheimer's disease. LX1001 targets APOE4 homozygous patients with Alzheimer's disease by delivering a functional APOE2 gene using the AAVrh10 vector. Its other product, LX2006, targets FA cardiomyopathy using the same vector. Read the full article on Seeking Alpha

Shareholder Returns

LXEOUS BiotechsUS Market
7D2.8%-2.4%0.7%
1Y7.8%35.9%20.6%

Return vs Industry: LXEO underperformed the US Biotechs industry which returned 35.9% over the past year.

Return vs Market: LXEO underperformed the US Market which returned 20.6% over the past year.

Price Volatility

Is LXEO's price volatile compared to industry and market?
LXEO volatility
LXEO Average Weekly Movement10.3%
Biotechs Industry Average Movement10.4%
Market Average Movement7.3%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: LXEO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: LXEO's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201759R. Townsendwww.lexeotx.com

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.

Lexeo Therapeutics, Inc. Fundamentals Summary

How do Lexeo Therapeutics's earnings and revenue compare to its market cap?
LXEO fundamental statistics
Market capUS$378.47m
Earnings (TTM)-US$87.50m
Revenue (TTM)n/a
0.0x
P/S Ratio
-4.3x
P/E Ratio

Is LXEO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LXEO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$62.33m
Gross Profit-US$62.33m
Other ExpensesUS$25.17m
Earnings-US$87.50m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.11
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LXEO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 01:36
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lexeo Therapeutics, Inc. is covered by 10 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
Yevgeniya LivshitsChardan Capital Markets, LLC